Human Anti-CD37 Recombinant Antibody (clone B2); scFv Fragment (CAT#: HPAB-AP034-YC-S(P))

Figure 1 Whole Blood Assay: Effect of Antibodies A2 and B2 ON Viable CLL Cells.

Whole blood samples from CLL patients were incubated with increasing concentrations (0.001 μg/ml to 100 μg/ml) of antibodies A2 and B2 for 3 hours. The percentage of viable CLL cells at the end of the incubation period in relation to antibody concentration is depicted, curves represent mean of 11 individual patient samples. Standard deviation for each concentration tested is indicated. A2: filled triangle; B2: open triangle. Dotted line represents activity of an isotype matched control antibody.

Figure 2 Whole Blood Assay with CLL Patient Samples: Comparison of Different Antibodies.

Blood samples were incubated with 10 μg/ml of antibodies A2, B2, rituximab, alemtuzumab and an isotype matched control antibody for 3 hours. The percentage of viable CLL cells at the end of the incubation period is depicted, bars represent mean of 11 patient samples. Standard deviation is indicated. Dotted line represents activity of the isotype matched control antibody.

Figure 3 Whole Blood Assay with CLL Patient Samples: Comparison of Different Patient Subgroups.

Blood samples are incubated with 10 μg/ml of antibodies A2, B2, rituximab and alemtuzumab for 3 hours. The percentage of viable CLL cells at the end of the incubation period for different patient subgroups is depicted, bars represent mean of the indicated number of patient samples. Standard deviation is indicated.

Figure 4 Whole Blood Assay with CLL Patient Samples: Comparison of Different Patient Subgroups.

Blood samples from normal risk patients (n=11) and high risk patients (n=10) were incubated with 10 μg/ml of antibodies A2, B2, rituximab and alemtuzumab for 8 hours. The percentage of viable CLL cells at the end of the incubation period for the two patient subgroups is depicted, bars represent mean values, standard deviation is indicated.

Figure 5 Binding to FCγ-Receptor 3A

The affinity of antibodies A2 and B2 to Fcγ-receptor 3a is determined by surface plasmon resonance analysis (SFP).